Chapter

Recently approved long-acting antipsychotic injections: paliperidone LAI and olanzapine LAI*

John Lauriello and Niels Beck

in Antipsychotic long-acting injections

Published on behalf of Oxford University Press

Published in print October 2010 | ISBN: 9780199586042
Published online February 2013 | e-ISBN: 9780191754708 | DOI: http://dx.doi.org/10.1093/med/9780199586042.003.0006
Recently approved long-acting antipsychotic injections: paliperidone LAI and olanzapine LAI*

Show Summary Details

Preview

The introduction of paliperidone LAI and olanzapine LAI are significant pharmacotherapeutic developments. Each antipsychotic offers the advantages of up to once a month injection intervals—an improvement over twice monthly risperidone LAI. Paliperidone LAI was developed in part to overcome some of the problems seen with risperidone LAI, especially the need to supplement risperidone LAI for at least 3 weeks with oral medication. Olanzapine LAI offers an alternative for those patients who have had a good response to oral olanzapine but have a history of poor adherence. In addition, there are clearly a number of patients who do not tolerate or respond to the risperidone family of medications and may respond to olanzapine and vice versa. Olanzapine LAI poses a unique challenge in its association with PDSS, but risk mitigation programmes should allow its use. Although the addition of these two medications is long overdue, the psychiatric field is in need of more long-acting antipsychotics and several others are in development, including an LAI of aripiprazole. These are welcome events as they increase the choice of medications available to patients and clinicians.

Chapter.  6185 words.  Illustrated.

Subjects: Psychiatry

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.